Table 1 Traditional risk factors in systemic sclerosis patients and healthy controls
From: Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors
Characteristic | Patients (n = 49) | Controls (n = 32) | P value |
|---|---|---|---|
Age, years | 55.4 ± 11.6 | 50.9 ± 10.1 | 0.078 |
Male gender, number (percentage) | 8 (16%) | 3 (9.4%) | 0.513 |
Body mass index, kg/m2 | 23.7 ± 2.9 | 24.0 ± 2.9 | 0.582 |
Smoking | Â | Â | Â |
   Pack years for smokers, number (percentage) | 3 (6%) | 2 (6.5%) | 1.000 |
   Median (range) | 20 (1–48) | 10 (6–14) |  |
Diabetes mellitus, number (percentage) | 2 (4%) | 0 | 0.523 |
Hypertension treated with antihypertensive agents, number (percentage) | 12 (24%) | 2 (6%) | 0.120 |
Blood pressure, mm Hg | Â | Â | Â |
   Systolic | 120 (110–135) | 120 (110–125) | 0.409 |
   Diastolic | 75 (70–80) | 75 (70–80) | 0.379 |
Cholesterol, mmol/L | Â | Â | Â |
   Total | 5.22 ± 1.00 | 5.53 ± 1.06 | 0.217 |
   Low-density lipoprotein | 3.02 ± 0.85 | 3.06 ± 1.08 | 0.871 |
   High-density lipoprotein | 1.40 (1.23–1.80) | 1.68 (1.48–1.89) | 0.027 |
Triglycerides, mmol/L | 1.36 (1.16–2.14) | 1.17 (0.77–1.67) | 0.030 |
Lipid-lowering drugs, number (percentage) | 7 (14%) | 0 | 0.038 |
   Simvastatin, number (mean dose in milligrams) | 4 (20) | 0 |  |
   Atorvastatin, number (mean dose in milligrams) | 2 (25) | 0 |  |
   Rosuvastatin, number (mean dose in milligrams) | 1 (10) | 0 |  |
Family history of cardiovascular disease, number (percentage) | 10 (20%) | 5 (16%) | 0.603 |
Cardiovascular history, number (percentage) | 4 (8%) | 0 | 0.149 |
   Cardiovascular | 1 |  |  |
   Cerebrovascular | 1 |  |  |
   Peripheral vascular disease | 2 |  |  |
C-reactive protein, mg/L | 3.5 (1.6–7.0) | 0.8 (0.3–2.0) | < 0.001 |